WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Myelodysplastic syndrome

Jyoti Kanojiya[1], Miss Aasawaree Mane[2], Dr. Rupali Tasgaonkar[3]

Mentor- Miss Aasawaree Mane, Dr. Rupali Tasgaonkar
Bachelor of Pharmacy,
Yadavrao tasgaonkar Institute of Pharmacy, University of Mumbai, Mumbai.

ABSTRACT:

Simple summary: The incapacity of the bone marrow to generate an adequate quantity of peripheral blood cells is the hallmark of myelodysplastic syndrome (MDS), a disease of the bone marrow. Skin samples in these cases are tainted by neoplastic variations, leading to a finding of missing variants. Using a multi-institutional cooperative group mechanism, The National Myelodysplastic Syndromes (MDS) Study (NCT02775383) recruited 2000 patients with MDS, patients with MDS/myeloproliferative neoplasms overlap disorder, and 500 patients with idiopathic cytopenia of unknown significance. The study of the germline germ line tissues for optimal detection of somatic variants in myelodysplastic disorders informs this study. Additionally, there is a chance of developing serious infections. Developing preventative strategies to treat patients more successfully and lower the incidence of disease to lower mortality is the ultimate objective.

Keywords: Myelodysplastic syndrome: prevalence, incidence, therapy, bacterial infection, early detection.

Introduction:

Blood-forming stem cell clonal diseases known as myelodysplastic syndromes (MDS) are primarily seen in older people. Acute myeloid leukemia (AML) is most likely to develop as a result of inadequate hematopoiesis, which causes blood cytopenia. Although they are mostly associated with aging, prior chemotherapy (particularly with alkylating drugs), radiation therapy, and exposure to benzene derivatives can also cause it. For individuals with myelodysplastic syndromes (MDS), risk stratification is crucial. Ten percent or so have a complex karyotype (CK), a highly unfavorable prognostic sign defined as more than two cytogenetic abnormalities. Analyzed data that the International Working Group for MDS supplied from 359 patients with CK-MDS [1,2]. All variants were underrepresented, except TP53 mutations, which were found in 55% of cases.

To improve risk stratification for patients with complex karyotype MDS, risk-associated markers are analyzed, including the presence of MK, particular chromosomal lesions, the total number of lesions, clinical variables, and TP53 mutations [3]. The goal is to identify the features that have independent prognostic value. The very high rate of disease progression to the stage of acute myeloid leukemia (AML) led to the long-term classification of myelodysplastic syndromes (MDS) as preleukemic diseases.

The manifestation code for MDS in the International Classification of Diseases for Oncology (ICD-O) was revised by the World Health Authority (WHO) in 2000 from 1 (i.e., unsure whether benign or malignant) to 3 (i.e., malignant). Afterward, in 2001, MDS started to be reported to population-based cancer registries, such as the US National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Programmes. This allowed population-level data on MDS morbidity and mortality to be obtained. An essential step towards improving the description of the morbidity and mortality of the illness is the inclusion of MDS in cancer reporting [3,4].

Etiology:

The prognosis for MDS patients is significantly worse if they have previously had cancer treatment, as they are more likely to have "secondary" or "therapy-related" MDS. Ionizing radiation, treatment for past cancer, and benzene exposure at work are some of the risk factors for MDS that are taken into account. MDS risk is known to be elevated by congenital conditions like Fanconi anemia. The most common sources of benzene exposure in the general population are pesticides, cigarette smoke, and solvent exposure (from things like painting or occupational exposure). There have been contradictory findings from many research on the relationship between alcohol use and MDS. Some studies found no correlation between alcohol use and the risk of MDS [5].

Diagnosis of MDS:

The primary indicator of MDS is bone marrow failure, which is brought on by the cloning of mutant hematopoietic stem and progenitor cells (HSPCs) in a supportive environment. In 85% of instances, the bone marrow is normal or hypercellular; in contrast, 15% of individuals have hypoplastic MDS

(the HMDS compound) in patients with MDS [6]. MDS may be identified from aplastic anemia and other myeloid neoplasms based on the presence of >10% dysplasia in one or more cell lineages and by karyotypic anomalies associated with MDS, such as del(5q), monosomy 7, and trisomy 8.

MDAcute myeloid leukemia is a possible outcome for MDSs, a diverse group of myeloid neoplasms that are defined by cytopenia, variable degrees of dysplasia, and cytopenia. MDS can show clinically as an indolent condition with few symptoms and moderate cytopenia, or as subgroups that are more akin to AML. Due to the long-established recognition of this clinical variability, MDSs have been divided into several subtypes according to their clinical, morphological, and genetic characteristics[6,7]. Nevertheless, the International Prognostic Scoring System (IPSS) was created since this categorization was insufficient for making predictions and choosing a course of therapy.

This risk stratification system is based on the percentage of bone marrow blasts, cytogenetic abnormalities, and the number of cytopenia. The IPSS was built for use in MDS clinical trials and then modified in 2012 to the R-IPSS, rating the severity of each cytopenia and expanding the genetic risk profile. Since then, our knowledge of the biology and genetics of cytopenia. MDS has improved with the widespread adoption of NGS: n, which has enabled the identification of recurrent gene mutations during disease development [6–8]. As the functional consequences of these mutations have been characterized, new prognostic systems and therapeutic approaches have been proposed, promising a brighter future for the treatment and prevention of MDS.

Morbidity and mortality due to infection in myelodysplastic syndromes:

There is relatively little accurate information about the prevalence of MDS infection and the respective bacterial, fungal, and viral causes. Most of this information is retrospective. Some of these are threatened by inconsistencies in the definition of infectious cases or, although they originate from clinical trials, patient eligibility criteria may be biased. Infection accounted for 38% of all deaths in a large US retrospective cohort of 273 untreated low- or intermediate-1-risk MDS patients who passed away between 1980 and 2004 [9]. AML transformation and hemorrhage accounted for 15% and 13% of all deaths, respectively.9. Pneumonia accounted for 40% of all infectious deaths, making it the most prevalent infection. Thirty percent of these MDS patients had pneumonia cases with microbiologically confirmed infections, most of which had bacterial origins. Because this study spanned three decades, it was feasible to demonstrate a discernible decline in the incidence of infected mortality over time, which is probably due to better supportive treatment [9-10].



Figure 1. Main risk factors of infection in myelodysplastic syndromes.

In a US survey conducted between 2003 and 2005, 1.3 million individuals over 65 were included. Of these, patients with MDS had a higher prevalence of infections than the non-MDS Medicare population (22.5% vs. 6.1%; P<0.001). Medicare is an insurance program that covers over 97% of all US citizens who are 65 years of age or older. Patients with MDS with diverse comorbidities, such as diabetes, dyspnea, and hepatic disorders, also showed a discernible difference, but the difference was more noticeable in those who had undergone transfusions.

Deficiencies in neutrophil granule contents are also present in MDS patients; these include abnormalities in lactoferrin, myeloperoxidase, and

antibiotic proteases like cathepsin G and elastase, as well as deficiencies in granule membrane glycoproteins44 and matrix metalloproteinase dysfunction. 47–49 Increased susceptibility to infections may be caused by impaired action of granule proteases in neutrophils, which can cause tissue damage through an inflammatory-mediated mechanism, even in the absence of neutropenia [11]. 50–52 Clinical investigations haven't yet provided a clear definition for these problems, though.

T-cell deficit - The majority of MDS patients experience lymphocytopenia, mostly as a result of a decline in T-helper cell numbers.53,57 The Patients with MDS were shown to have an altered balance between CD4+ TH1 cells and TH2 cells, with a drop in the number of TH1 cells and a lower TH1:TH2 ratio.

Neutropenia, which can deteriorate spontaneously or temporarily as a result of therapy, is most likely the main cause of the elevated risk of infection in MDS patients [11-12]. Nevertheless, qualitative neutrophil defects, other immunological problems that are less well-known, and iron excess in some cases may further increase the risk of infection.

prognostic factors:

According to research of SEER data on MDS from 2001 to 2008, the observed 3-year and 5-year survival rates are 42% and 29%, respectively.8 Earlier research has found a variety of prognostic variables, including cytogenetics, age, sex, bone marrow blast proportion, MDS subtype, transfusion dependency, and number of cytopenias.26, 27.

According to predictive models like the International Predictive Scoring System (IPSS), the last three disease characteristics are important determinants of prognosis for MDS patients.27 The WHO-based Prognostic Scoring System (WPSS) includes transfusion dependency as a major consideration in addition to the karyotype and MDS subtype.28 More recently, we found that socioeconomic status (30) and comorbidities (29), in a sample of about 2,000 individuals 65 years of age who were diagnosed with MDS in 2001 and 2002, were significant and independent. The possibility of administering anthracyclines, one of the main chemotherapy drugs, to an MDS patient who develops AML may be limited if they have CHF. agents for leukemia because of their potential harm to the heart. Considering that a "typical" aged cancer patient has three or more concomitant conditions,31 it is important to evaluate the significance of each common illness for the prognosis of MDS as well as any potential interactions between them. Additionally, while assessing treatment choices, doctors may find it crucial to take comorbidities into account when risk-stratifying patients with MDS [13].

Prevention:

Growth factors: Neutropenia will usually occur and is typically substantial in patients on lenalidomide who have low-risk MDS and del 5q, as previously indicated. To prevent perhaps

Experts advise using G-CSF anytime ANC falls below 1.0×109/L to prevent deadly infections (as shown in the initial studies with this agent).169 This strategy may help prevent dosage decreases that are linked to decreased lenalidomide-induced cytogenetic responses, as demonstrated by a combined analysis of the MDS 003 and MDS 004 trials in lower-risk MDS patients with del 5q. But, considering that lenalidomide also induces thrombocytopenia, it is still unclear if using G-CSF in this situation can support maintaining a higher dose of the medication [13-14].

Management of contagious episodes-

Information on infection risk and neutropenia should be provided to patients with MDS. Individuals taking lenalidomide, chemotherapy, or hypomethylating medications may experience variable periods of worsening. Individuals receiving supportive treatment alone may not experience significant changes over time [15].

Since induced neutropenia can be severe and occurs in individuals who were not typically neutropenic at baseline, neutropenic episodes linked to lenalidomide therapy are especially crucial to watch. Patients with fevers should get tested in every way, including blood cultures, and they need broad-spectrum empirical antibiotics. Hospital admission is necessary to prevent serious consequences. The selection of the antibacterials must be guided by clinical manifestation, the infection's intensity, and the local epidemiology. The hazards of infection should also be very clear to the general practitioner [15-16].

Recommendations for treatment based on individual risk and the kind of myelodysplastic syndrome medication-

Preventive actions have to be taken into consideration in particular clinical circumstances. It is well acknowledged that neutropenia in and of itself does not justify the provision of preventive anti-infectives to patients receiving supportive treatment alone. The primary cause is that the length of neutropenia would need months or years of nonstop antibacterial or antifungal medication usage. This would probably result in an intolerable risk of drug-generated side effects as well as induced resistance, which has been demonstrated in the case of long-term therapy with quinolones179,180 and antifungal triazoles 175,176 [17]. During the first course of treatment, more than half of lenalidomide patients experience grade 3–4 neutropenia, and ANC levels of individuals taking this medication should, Consequently, be observed often. However, there is no evidence to recommend the regular prescription of preventative antifungals or antibiotics. Given that neutropenia is a limiting side-effect of lenalidomide,99 therapy modification is essential. A panel of specialists suggested giving G-CSF to patients whose baseline or ongoing ANC levels were less than 1.0×109/L.

Chelation of iron –

The primary objective of iron chelation has been to repair organ damage caused by iron excess, particularly in the liver and heart, and the possible benefit of lowering the risk of infection has received little consideration [17-18].177 It is yet unknown if iron chelation can lower the risk of infection. For iron-deficient patients, including those with MDS, who are candidates for HCT, iron chelation is presently advised before to transplant.74,8.Although the exact processes underlying its beneficial benefits in this case are still mostly understood, they may include lowering the risk of infection.

prevention with antifungals

Regarding IFI, prospective controlled data are only accessible for MDS patients undergoing intense AML treatment. chemotherapy. In this case, posaconazole, as opposed to itraconazole or fluconazole, significantly decreased the incidence of proven and probable IFI in a cohort of 602 patients whose mean duration of chemotherapy-induced severe neutropenia was 24 days.93 However, only 14.5% of the individuals in that group had MDS that developed into AML, whereas the remaining patients developed AML from scratch [19]. Furthermore, the majority of patients with MDS who are at increased risk now take hypomethylating medications; it is uncertain if antifungal prophylaxis works well in these individuals. Primary fungal prophylaxis should be used if the incidence of IFI in MDS is similar to that observed before the advent of hypomethylating drugs (2% in the Italian experience126). is not advised as a course of care. This is because, in contrast to AML or allogeneic HCT recipients, the incidence in MDS patients is below the standard rate of at least 5%, which is often seen to warrant primary prophylaxis.174. Additionally, individuals with MDS may experience protracted neutropenia, necessitating long-term preventive triazoles; this has been linked to an increased risk of developing acquired resistance to those medications.175,176 Therefore, outside of controlled trials, antifungal prophylaxis with triazoles cannot presently be advised for MDS patients taking hypomethylating medications [20-21].

Radiation Therapy's Risks:

As the size of radiotherapy fields grew, so did the danger of radiation, according to the univariate analysis. Taking patients into mind for patients who received only local breast radiation, the risk increased by 2.39 (95% CI, 0.84 to 6.77) compared to the reference group. For patients who received regional radiation (nodes breast), the risk increased by 5.17 (95% CI, 1.98 to 13.5), and for those who received radiation therapy to distant sites (radiotherapeutic ovarian ablation or irradiation of metastatic sites), the risk increased by 8.21 (95% CI, 2.50 to 27). In patients receiving radiotherapy, an increase of 1 Gy was linked to a risk ratio of 1.14 (95% CI, 1.04 to 1.25). In the univariate analysis, the risk rose with the mean radiation dose received by active bone marrow [22].

Table 1. Incidence of infectious complications, and infectious deaths in the larger prospective or observational trials using hypomethylating agents in myelodysplastic syndromes.

According to IWG 2006 criteria, According to the National Cancer Institute Common Toxicity Criteria

Reference	Study design	Hypomethylating agent	N. patients treated with hypomethylating agents	Median n. cycles (range)	Overall response rate (%) of hypomethylating agent groups	Rate of infectious complications	Death from infections (%) in the homomethylating agent group
Silverman LR JCO 2002	Prospective, randomized Azacitidine vs. supportive care	Azacitidine 75 mg/m/d, SCx7d, every 28 days	99	-	60%	# 20%	Not available
Silverman LR JCO 2006	The sum of 3 prospective trials, including Silverman *et al.2002*	"	268	-	36-48%	0.64 infection per pt/year in Aza *vs.* 0.95 in supportive care	3 patients (2%) of 150 pts at cycles 2, , 4 and 68

Fenaux P Lancet Oncol 2009 AZA-001	Prospective, randomized, open, high-risk, Azacitidine vs. supportive care or LD-AraC or intensive chemotherapy Azacitidine	"	179(including 34% of RAEB-t and 47% IPSS high-risk)	9 (4-15)	Any remission: 29% improvement: 49%	Infections treated by IV antibacterials/pt/y: 0.60 *vs.* 0.92 in the control group (*P*=0.0032)	Not available
Musto P Cancer 2010	Retrospective, compassionate use of azacitidine in lower-risk MDS	Azacitidine SC (different schedules)	74(all low or intermediate risk) 51% > 70 years	7 (1-30)	45.9%	* Grade 1-2+: 2.7% Grade 3-4: 6.8%	0
Garcia-Manero G JCO 2000	Phase I, maximum-tolerated dose study	Azacitidine, orally	41	4.5 to 12.5 (variable according to the disease) (1-32)	35% if previously treated, 73% if previously untreated	Grade 3 febrile neutropenia: 8(19.5%)	
Wijermans P JCO 2000	Prospective, open, phase II, Int I or II, or high risk	Decitabine (45mg/m/d for 3days every 6 weeks	66(179(including 30% of RAEB-t)	Not available	66%	Fever, infection, and septicemia: 38 patients/66 (57%) and 44 episodes/162 (27%) cycles	
Issa JP Blood 2004	Prospective, phase I, multiple low-dose longer exposure schedules	7 different regimens of decitabine	50(including only 7 patients with MDS)	Not available	4/7 in the MDS patients In the whole cohort: 32%	No specific information for the 7 MDS patients of the overall cohort: 26 (52%) patients with a febrile episode (FUO:8, clinically documented: 18 including 6 bacterial and 1 fungal infection	
Kantarjian H Caner 2006	Prospective, comparative, decitabine Vs. best supportive care, IPSS>0.5	Decitabine IV (15mg/m x3/d till135 mg/m/course) every 6 weeks	89(including 19% of RAEB-t)	3 (0-9)	30%*	Febrile neutropenia grades3 or 4: 23/83 (27.7%) Pneumonia: 15/83 (18%)	Not available
Kantarjian H Caner 2007	Prospective, comparative, study of 3 decitabine regimens in high-risk	Decitabine 20mg/m/d IV x 5 days or 20 mg/m/d SC x5 days 0r 10mg/m/d IV x10 days every 4 weeks	95(including 46% in 2 and 20% high-risk)	6 (1-18)	73%	Fever of unknown origin: 23/622 cycles (4%/cycle) 7(1%) sepsis, 24 (4%/cycle) documented minor infections 20 (3.5%) Pneumonia 7 (1%/cycle) fungal infections	Unknown. No death directly attributed to decitabine therapy

Conclusion:

MDS affects a significantly younger population than usual. Following the discovery of pre-MDS lesions (CHIP and CCUS), persons with these disorders are now given extra care to watch for the emergence of blood malignancies and unfavorable cardiovascular results. Finding those who are most at risk of myeloid cancer and taking action to stop the disease's spread is the long-term objective. It also examines a large cohort of CK-MDS

patients to find strong associations between clinical and genetic disease features including OS. The findings in Tp53 support modifications to the standard of care for CK-MDS patients to include routine genetic sequencing. MDS develop common bacterial infections when they are profoundly neutropenic. Other mechanisms contribute to immune suppression.

REFERENCES:

1. Genetics of Myelodysplastic Syndromes by Saygin, C. and Godley, L.A. 2021, 13, 3380; Cancers.
2. Rodriguez-Santiago, B.; Hutchinson, A.; Deng, X.; Liu, C.; Horner, M.J.; Jacobs, K.B.; Yeager, M.; Zhou, W.; Wacholder, S.; Wang, Z.; et al. The association between cancer and aging and detectable clonal mosaicism. Nature Genetics, 44 (2012), 651–658.
3. Abelson, S.; Niemeyer, E.; Barda, N.; Zuzarte, P.C.; Heisler, L.; Sundaravadanam, Y.; et al.; Collord, G.; Ng, S.W.K.; Weissbrod, O.; Mendelson Cohen, N. estimation of the risk of acute myeloid leukemia in healthy people. 2018; Nature 559, 400–404.
4. Germ line tissues for optimum detection of somatic variations in myelodysplastic syndromes, Padron, E., Ball, M.C.; Teer, J.K.; Painter, J.S.; Yoder, S.J.; Zhang, C.; Zhang, L.; Moscinski, L.C.; Rollison, D.E.; Gore, S.D.; et al. 2018, 131, 2402–2405 in Blood.
5. Leukaemia (2019) 33: 1747–1758; doi: 10.1038/s41375-018-0351-2.
6. Bejar R. Prognostic factors for myelodysplastic syndromes: clinical and genetic factors. Journal of Hematology. 2014;99:956–64.
7. Bally C, Ades L, Preudhomme C, Renneville A, Sebert M, Eclache V, and others. prognostic significance of TP53 gene mutations in acute myeloid leukemia treated with azacitidine and myelodysplastic syndromes. Res Leuk. 2014;38:751–5.
8. Specchia G, Albano F, Anelli L, Pasciolla C, Zagaria A. Reviews of the literature on monosomal karyotype in myeloid neoplasias. Therapeutic Interventions. 2017;10:2163–71.
9. Mohamedali AM, Sharmamurthy P, Lea NC, Kulasekararaj AG, Smith AE, Mian SA, et al. Adverse prognosis is highly linked with chromosomal 5 abnormalities in myelodysplastic syndrome caused by TP53 mutations. Br J Hematol. 2013; 160:660–72.
10. Munich Leukaemia Laboratory (MLL), Munich, Germany.
11. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al: International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.
12. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed 5. Lyon,
1. IARC, 2017.
13. 1Department of Hematology, Assistance Publique-Hôpitaux de Paris (APHP).
14. Tefferi A, Vardiman JW. Myelodysplastic
2. syndromes. N Engl J Med. 2009;361(19):
3. 1872-85.
15. Fenaux P, Rose C. Impact of iron overload in myelodysplastic syndromes. Blood Rev.
4. 2009;23(Suppl 1):S15-9.
16. Cunningham I, Hewson JW, Arnold B, Nicholls MD, Cunningham I, McCallum SJ, et al. Prognostic variables for 226 patients from a single institution related to myelodysplastic syndromes were analyzed.
17. The Department of Epidemiology and Public Health at Yale University School of Medicine, along with the Yale Comprehensive Cancer Centre, published a paper in 1995 (Br J Haematol. 1995;90(3):602–616).
18. Cheah, J.J.C.; Hahn, C.N.; Hiwase, D.K.; Scott, H.S.; Brown, A.L. Myeloid neoplasms with germline DDX41 mutation. Int. J. Hematol. 2017, 106, 163–174.
19. Carraway, H.E.; Saygin, C. Therapy for lower-risk MDS. Hematol. Am. Soc. Hematol. Educ. Program. 2020, 2020, 426–433.
20. Speck, N.A.; Gilliland, D.G. Core-binding factors in hematopoiesis and leukaemia. Nat. Rev. Cancer 2002, 2, 502–513.
21. Ozga, M.; Blachly, J.; Eisfeld, A.K.; Grieselhuber, N.; Larkin, K.;Walker, A.; Bhatnagar, B.; Behbehani, G.; Long, M.; Haque, T.; et al. Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms. Am. J. Hematol. 2021.
22. Andersson M, Storm HH, Mouridsen HT: Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 31:259-263, 1992.